Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome

References

• Heaney M L, Golde D W. Myelodysplasia. N Engl J Med 1999; 340: 1649–1660
   PubMed Web of Science ®Google Scholar
• Silverman L. The myelodysplastic syndrome. Decker, Hamilton, BC 2003
   Google Scholar
• Norfolk D R, Ancliffe P J, Contreras M, Hunt B J, Machin S J, Murphy W G, et al. Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27 – 28 November 1997. Synopsis of background papers. Br J Haematol 1998; 101: 609–617
   PubMed Web of Science ®Google Scholar
• Silberman S. Platelets: preparations, transfusion, modifications, and substitutes. Arch Pathol Lab Med 1999; 123: 889–894
   PubMed Web of Science ®Google Scholar
• Kurzrock R. Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited. Clin Cancer Res 2005; 11: 1361–1367
   PubMed Web of Science ®Google Scholar
• Saba H I. Myelodysplastic syndromes in the elderly: the role of growth factors in management. Leuk Res 1996; 20: 203–219
   PubMed Web of Science ®Google Scholar
• Kaye J A. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 1998; 16(Suppl 2)207–223
   PubMedGoogle Scholar
• Isaacs C, Robert N J, Bailey F A, Schuster M W, Overmoyer B, Graham M, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15: 3368–3377
   PubMed Web of Science ®Google Scholar
• Tepler I, Elias L, Smith J W, 2nd, Hussein M, Rosen G, Chang A Y, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607–3614
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Cortes J, Thomas D A, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001; 19: 4165–4172
   PubMed Web of Science ®Google Scholar
• Tsimberidou A M, Giles F J, Khouri I, Bueso-Ramos C, Pilat S, Thomas D A, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol 2005; 16: 139–145
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kantarjian H, Pinto A, Schiffer C A, Nimer S D, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–364
   PubMed Web of Science ®Google Scholar
• Bernasconi C, Alessandrino E P, Bernasconi P, Bonfichi M, Lazzarino M, Canevari A, et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998; 102: 678–683
   PubMed Web of Science ®Google Scholar
• Chuncharunee S, Intragumtornchai T, Chaimongkol B, Prayoonwiwat W, Leelasiri A, Lekhakula A, et al. Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor: a multicenter study. Int J Hematol 2001; 74: 144–146
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl I M, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68–75
   PubMed Web of Science ®Google Scholar
• Negrin R S, Haeuber D H, Nagler A, Kobayashi Y, Sklar J, Donlon T, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 76: 36–43
   PubMed Web of Science ®Google Scholar
• Remacha A F, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 1999; 84: 1058–1064
   Google Scholar
• Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, et al. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia 1999; 13: 1009–1012
   PubMed Web of Science ®Google Scholar
• Thompson J A, Gilliland D G, Prchal J T, Bennett J M, Larholt K, Nelson R A, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 2000; 95: 1175–1179
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Keating M, LeMaistre A, Hittelman W N, McCredie K, Trujillo J M, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1545–1552
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Talpaz M, Estey E, O'Brien S, Estrov Z, Gutterman J U. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 1991; 5: 985–990
   PubMed Web of Science ®Google Scholar
• Verhoef G E, Zachee P, Ferrant A, Demuynck H, Selleslag D, van Hove L, et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Hematol 1992; 64: 16–21
   PubMed Web of Science ®Google Scholar
• Du X X, Neben T, Goldman S, Williams D A. Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. Blood 1993; 81: 27–34
   PubMed Web of Science ®Google Scholar
• Kuter D J. Future directions with platelet growth factors. Semin Hematol 2000; 37(2 Suppl 4)41–49
   PubMed Web of Science ®Google Scholar
• Nash R A, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000; 6: 25–34
   PubMed Web of Science ®Google Scholar
• Adams J A, Liu Yin J A, Brereton M L, Briggs M, Burgess R, Hyde K. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia. Br J Haematol 1997; 99: 139–146
   PubMed Web of Science ®Google Scholar
• Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404–409
   PubMed Web of Science ®Google Scholar
• Fontenay-Roupie M, Dupont J M, Picard F, Fichelson S, Botella A, Melle J, et al. Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leuk Res 1998; 22: 527–535
   PubMed Web of Science ®Google Scholar
• Schuster M W, Beveridge R, Frei-Lahr D, Abboud C N, Cruickshank S, Macri M, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002; 30: 1044–1050
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Talpaz M, Estrov Z, Rosenblum M G, Gutterman J U. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991; 9: 1241–1250
   PubMed Web of Science ®Google Scholar
• Wu H H, Talpaz M, Champlin R E, Pilat S R, Kurzrock R. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer 2003; 98: 2410–2419
   PubMed Web of Science ®Google Scholar
• Kurzrock R. Trilineage responses seen with stem cell factor and filgrastim treatment in aplastic anemia patients. Br J Haematol 1998; 102(1), abstract PL-0004
   Web of Science ®Google Scholar
• Gordon M S, Nemunaitis J, Hoffman R, Paquette R L, Rosenfeld C, Manfreda S, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066–3076
   PubMed Web of Science ®Google Scholar